最新消息 生華科新藥入選美國國家隊 獲五年共同開發計畫與經費贊助 Dec 01 2022 最新消息 生華科新藥助攻輝瑞 併用PARP抑制劑治療攝護腺癌 Oct 31 2022 最新消息 生華科新總座上任 加速改革凝聚向心力 Oct 25 2022 媒體報導 生華科持續開發新冠新藥 向台灣申請二期臨床試驗 Mar 01 2023 媒體報導 生華科(6492)新藥CX-5461繼獲輝瑞認同後,再入選美國NIH抗癌國家隊全速推進新藥上市 Dec 01 2022 媒體報導 生華科 新總座三箭衝業績 Nov 16 2022 期刊 Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 期刊 Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 期刊 Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study. Jan 12 2021